Summary Companies who pay for stock promotion should be avoided. Period. Sell side research is woefully deficient and predictably biased. With technology, you get what you pay for. Lack of institutional ownership is a strong predictor of failure. Share price is a poor predictor of ultimate success. This article is the opinion of the author….

Read More

Summary A recent report from Vista Partners sent OHRP soaring by 60%. The contents, including a $31 price target, was provided and paid for by Ohr management. Ohr stock had just collapsed to as low as $6.86 due to a recent failure of its drug in clinical trials. Squalamine was previously owned by Genaera Pharma….

Read More